Midwest Trust Co Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

Midwest Trust Co purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in the 2nd quarter, Holdings Channel reports. The firm purchased 571 shares of the pharmaceutical company’s stock, valued at approximately $254,000.

A number of other institutional investors have also made changes to their positions in the business. Brighton Jones LLC grew its position in Vertex Pharmaceuticals by 15.0% in the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after purchasing an additional 579 shares in the last quarter. CWM LLC boosted its stake in shares of Vertex Pharmaceuticals by 22.3% during the 1st quarter. CWM LLC now owns 7,684 shares of the pharmaceutical company’s stock worth $3,725,000 after buying an additional 1,403 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its stake in shares of Vertex Pharmaceuticals by 13.8% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 552 shares of the pharmaceutical company’s stock worth $268,000 after buying an additional 67 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Vertex Pharmaceuticals by 72.0% in the 1st quarter. Larson Financial Group LLC now owns 836 shares of the pharmaceutical company’s stock valued at $405,000 after acquiring an additional 350 shares in the last quarter. Finally, Bryn Mawr Capital Management LLC acquired a new stake in shares of Vertex Pharmaceuticals in the first quarter valued at about $221,000. Institutional investors own 90.96% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on VRTX. Wall Street Zen cut Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 22nd. Raymond James Financial started coverage on Vertex Pharmaceuticals in a research note on Tuesday, September 2nd. They set a “market perform” rating on the stock. Guggenheim cut their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Stifel Nicolaus lowered their target price on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating on the stock in a report on Tuesday, November 4th. Finally, HC Wainwright dropped their price target on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eleven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $491.95.

Vertex Pharmaceuticals Trading Up 0.1%

Shares of NASDAQ VRTX opened at $434.52 on Friday. The company has a market capitalization of $110.25 billion, a P/E ratio of 31.06 and a beta of 0.36. Vertex Pharmaceuticals Incorporated has a 12 month low of $362.50 and a 12 month high of $519.68. The stock has a 50 day moving average of $407.22 and a 200-day moving average of $428.25.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter last year, the firm posted $4.38 EPS. The company’s quarterly revenue was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.